Organon & (US:OGN) ZACKS·2025-07-18 22:51Company Performance - Organon (OGN) shares decreased by 1.87% to $9.46, underperforming the S&P 500's slight loss of 0.01% on the same day [1] - Over the past month, Organon shares have declined by 2.43%, compared to a 1.59% loss in the Medical sector and a 5.37% gain in the S&P 500 [1] Upcoming Earnings - The upcoming earnings release is anticipated, with an expected EPS of $0.94, reflecting a 16.07% decrease from the same quarter last year [2] - Revenue is forecasted at $1.55 billion, indicating a 3.35% decline compared to the same quarter of the previous year [2] Fiscal Year Estimates - For the entire fiscal year, earnings are projected at $3.83 per share, representing a -6.81% change from the previous year [3] - Revenue for the fiscal year is estimated at $6.24 billion, showing a -2.48% change from the prior year [3] Analyst Estimates - Recent adjustments to analyst estimates for Organon reflect changing short-term business dynamics, with positive revisions indicating analysts' confidence in performance [4] - The Zacks Rank system, which incorporates estimate changes, suggests a correlation between these revisions and stock price performance [5] Zacks Rank and Valuation - Organon currently holds a Zacks Rank of 2 (Buy), with a 0.55% increase in the consensus EPS estimate over the past month [6] - The company is trading at a Forward P/E ratio of 2.52, significantly lower than the industry average of 15.4, indicating a discount [7] - Organon has a PEG ratio of 0.96, compared to the industry average of 1.52, suggesting favorable valuation relative to growth expectations [7] Industry Context - The Medical Services industry, part of the Medical sector, has a Zacks Industry Rank of 90, placing it in the top 37% of over 250 industries [8] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]